NCT03970096 2026-03-12
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
Phase 2 Recruiting
Clinical Trials
10 trialsNCT03277729 2026-01-05
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
Phase 1/2 Active not recruiting
NCT03708003 2025-12-30
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase 2 Terminated
NCT07292272 2025-12-26
Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
University of Nebraska
Phase 2 Not yet recruiting
NCT05065866 2025-12-04
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03670966 2025-10-16
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT05507827 2025-09-16
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
Stanford University
Phase 1 Active not recruiting
NCT05871008 2025-09-15
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
Phase NA Active not recruiting
NCT06516679 2025-07-03
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
Yonsei University
Phase 2 Recruiting
NCT03219450 2025-05-22
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Dana-Farber Cancer Institute
Phase 1 Recruiting